Author: Fathi, Anahita; Dahlke, Christine; Addo, Marylyn M.
Title: Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens Document date: 2019_9_5
ID: 4cia91cq_30
Snippet: Marburg hemorrhagic fever, caused by Marburg virus (MARV) of the genus Marburgvirus, is characterized by its high casefatality rate. Also belonging to the family of Filoviridae, MARV shares a lot of characteristics with EBOV. However, historically less frequent outbreaks with fewer affected individuals have occurred. 86 It both poses a great potential public health threat as an emerging virus and is listed as a category A bioterrorism agent by th.....
Document: Marburg hemorrhagic fever, caused by Marburg virus (MARV) of the genus Marburgvirus, is characterized by its high casefatality rate. Also belonging to the family of Filoviridae, MARV shares a lot of characteristics with EBOV. However, historically less frequent outbreaks with fewer affected individuals have occurred. 86 It both poses a great potential public health threat as an emerging virus and is listed as a category A bioterrorism agent by the Center for Disease Control (CDC), making vaccine development a priority. Despite decades of research, no licensed vaccines or therapies are available to date. However, ample preclinical data on rVSV-vectored MARV vaccine candidates have been generatedoften alongside the EBOV vaccine candidates, both as a pre-exposure prophylactic as well as a postexposure vaccine (reviewed in 15, 87, 88 ).
Search related documents:
Co phrase search for related documents- Marburg virus and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- Marburg virus and public health threat: 1
- MARV Marburg virus and public health: 1, 2
- MARV Marburg virus and public health threat: 1
- marv vaccine candidate and vaccine candidate: 1, 2
- postexposure vaccine and public health: 1
- potential public health threat and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64
- potential public health threat and public health threat: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63
- potential public health threat and vaccine candidate: 1, 2
- potential public health threat and vaccine development: 1, 2, 3, 4, 5, 6
- public health and research decade: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- public health and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- public health and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- public health and vaccine development priority: 1, 2, 3
- public health threat and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- public health threat and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
- public health threat and vaccine development priority: 1
- research decade and vaccine development: 1
- research decade and vaccine development priority: 1
Co phrase search for related documents, hyperlinks ordered by date